DAFNE: authors' response to electronic letters from 5th October to 22nd October 2002. / DAFNE, Study Group; Heller , S; Speight, J; Amiel, S; Bradley, Clare; James, P; Roberts, S.
In: British Medical Journal, 29.10.2002.Research output: Contribution to journal › Letter
Published
Abstract
The rapid responses received following the publication of the DAFNE trial reflect the controversy surrounding the current inadequate management of Type 1 diabetes. [1] While it is true that the approach is not novel (Ullman, 5th Oct; Black,6th Oct; Reed, 9th Oct; Chaufan, 12th October, Cohen, 22nd Oct), it is new to the UK. The biomedical benefits of this intensified approach had been known for some time in parts of Europe [2,3] but is was unclear whether these could be transferred to a British health care setting. furthermore, the impact on quality of life was unknown, as psychological outcomes were not measured in the early German work.
| Original language | English |
|---|---|
| Journal | British Medical Journal |
| Publication status | Published - 29 Oct 2002 |
This open access research output is licenced under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
ID: 1417161